Octreotide Evidence Guide
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.
Our Take
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.
- Evidence context
- Acromegaly, carcinoid syndrome, VIPoma, GH/IGF-1 suppression, somatostatin analog pharmacology
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 100-600mcg daily subcutaneous (immediate release) or 20-30mg IM monthly (LAR)
Benefits and Evidence
- Acromegaly Control: Level A, includes human evidence - Normalizes GH and IGF-1 levels in approximately 50-70% of acromegaly patients. Long-acting formulation (LAR) allows monthly dosing with maintained efficacy.
- Carcinoid Symptom Control: Level A, includes human evidence - Effectively controls flushing and diarrhea in carcinoid syndrome. PROMID trial showed significant prolongation of time to tumor progression in metastatic midgut NETs.
- Gallstone Formation: Level A, includes human evidence - Gallstones or biliary sludge develop in 15-30% of patients on long-term therapy due to inhibition of gallbladder motility and bile secretion.
- VIPoma Symptom Control: Level A, includes human evidence - Dramatically reduces profuse watery diarrhea characteristic of VIPomas by inhibiting VIP secretion. Often life-saving in severe cases.
Side Effects and Warnings
- Diarrhea and steatorrhea
- Abdominal pain and nausea
- Cholelithiasis
- Injection site pain
- Hyperglycemia or hypoglycemia
- Bradycardia
- Gallstones - periodic gallbladder ultrasound recommended
- Glucose metabolism changes - monitor in diabetic patients
Research Dosage References
- <strong>Subcutaneous injection</strong> - 50-200 mcg - Two to three times daily - Immediate-release formulation. Starting dose typically 50 mcg three times daily for acromegaly. Titrate based on GH/IGF-1 response.
- <strong>Intramuscular injection</strong> - 20-30 mg - Every 28 days - Sandostatin LAR Depot. Start at 20 mg monthly after 2-week trial of SC octreotide. May increase to 30-40 mg based on response.
Mechanism of Action
Octreotide mimics somatostatin to suppress multiple hormonal pathways: 1. SSTR2/SSTR5 activation: Binds primarily to somatostatin receptor subtypes 2 and 5, mimicking the inhibitory effects of natural somatostatin with a much longer duration of action. 2. Growth hormone suppression: Inhibits GH secretion from somatotroph adenomas in acromegaly, reducing IGF-1 levels and associated symptoms. 3. Gastrointestinal hormone suppression: Inhibits release of serotonin, VIP, gastrin, secretin, and other GI peptide hormones, reducing symptoms of carcinoid syndrome and VIPomas. 4. Antiproliferative effects: Direct and indirect antiproliferative actions on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Legal Status
FDA-approved for acromegaly, severe diarrhea/flushing associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with VIPomas. Available by prescription. Marketed as Sandostatin by Novartis. Generic versions available.
Primary Sources
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID). J Clin Oncol, 2009.
- A meta-analysis of the efficacy of octreotide in acromegaly. J Clin Endocrinol Metab, 2005.
- Long-term treatment of acromegaly with octreotide. Ann Intern Med, 1992.
Quick Answers
Where is the strongest evidence for Octreotide?
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology. Evidence context: Acromegaly, carcinoid syndrome, VIPoma, GH/IGF-1 suppression, somatostatin analog pharmacology.
What are the main side effects of Octreotide?
Octreotide side effects and warning signals include Diarrhea and steatorrhea, Abdominal pain and nausea, Cholelithiasis, Injection site pain, and Hyperglycemia or hypoglycemia.
What evidence level is Octreotide?
Octreotide is rated Level A; the listed research status is FDA Approved.